Drug intelligence / Profile preview

Ambovex

Development stage: Unknown
Lead developer: AMKS Time Release
Administration: Oral

Overview

Ambovex is a pharmaceutical botanical drug described as an immune-modulator molecule that has been investigated for the treatment of hepatocellular carcinoma (HCC). [1, 2] In a Phase II clinical trial, Ambovex, administered as a low-dose oral spray, was found to be safe and demonstrated efficacy in reducing α-fetoprotein (AFP) levels and decreasing the number and size of liver lesions in patients with HCC. [1, 2] Some patients experienced a complete disappearance of lesions after six months of treatment. [1, 2] One source suggests the botanical medicine is derived from plants of the Ranunculaceae family. [6] Research also suggests it may have hepatoprotective effects in patients with Hepatitis C virus (HCV) by helping to reverse liver fibrosis. [10]

Brand names: Ambovex

Beyond the preview

Go deeper on Ambovex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ambovex.

Explore the full profile